Bladder Preservation Therapy Conducted by Intra-arterial Chemotherapy and Radiotherapy for Muscle Invasive Bladder Cancer
Open Access
- 7 April 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 39 (6) , 381-386
Abstract
A previous paper reported favorable results of intra-arterial chemotherapy in combination with radiotherapy for muscle-invasive bladder cancer. The current study will update those results. Between January 1992 and December 2006, 94 patients with confirmed muscle invasion were treated with intra-arterial chemotherapy and concurrent radiotherapy after an initial complete transurethral resection. Intra-arterial chemotherapy consisted of cisplatin (Days 1–3) and pirarubicin (Days 8–10), and radiation was administered with the chemotherapy (2 Gy/session) with a total dosage of 44 Gy. The median age was 67.0 years. There were 60 patients in T2, 19 patients in T3 and 15 patients in T4. The median follow-up period was 72.9 months in the survivors. Among these patients, 84 patients (89.4%) obtained a complete response (CR) and 10 patients did not achieve a CR. Between the CR and non-CR patients, the clinical stage and the existence of hydronephrosis were significantly different. The cause-specific survival rates at 5 and 10 years were 76.2% and 67.5%, respectively. The overall survival rates at 5 and 10 years were 66.6% and 47.4%, respectively. A Cox proportional hazard model showed that only the cause-specific survival rate was associated with a CR after treatment. The bladder preservation rates were 89.7% at 5 years and 87.6% at 10 years. Myelosuppression was the major adverse event but it was manageable. Non-hematological sever adverse events were rare. Bladder preservation therapy shows good survival and good bladder preservation rates. Clinical stage T2 and the absence of hydronephrosis are favorable factors.Keywords
This publication has 15 references indexed in Scilit:
- Health‐related quality of life after bladder preservation therapy for muscle invasive bladder cancerInternational Journal of Urology, 2008
- Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving TherapyJapanese Journal of Clinical Oncology, 2007
- Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research ConsortiumJournal of Urology, 2006
- Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapyUrology, 2004
- Clinical Outcome of a Large-Scale Multi-Institutional Retrospective Study for Locally Advanced Bladder Cancer: A Survey Including 1131 Patients Treated during 1990–2000 in JapanEuropean Urology, 2004
- Radical Cystectomy for Invasive Bladder Cancer: Results of Multi-institutional Pooled AnalysisJapanese Journal of Clinical Oncology, 2004
- Primary Cisplatin, Methotrexate and Vinblastine Chemotherapy With Selective Bladder Preservation for Muscle Invasive Carcinoma of the Bladder: Long-Term Followup of a Prospective StudyJournal of Urology, 2002
- A bladder preservation regimen using intra‐arterial chemotherapy and radiotherapy for invasive bladder cancer: A prospective studyInternational Journal of Urology, 2000
- Preliminary Results of Bladder Preservation by Concurrent lntraarterial Chemotherapy and Radiotherapy for Muscle-Invasive Bladder CancerInternational Journal of Urology, 1998
- Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of rtog protocol 85-12International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1993